Oral disease in adults treated with hemodialysis: prevalence, predictors, and association with mortality and adverse cardiovascular events: the rationale and design of the ORAL Diseases in…

Giovanni FM Strippoli, Suetonia C Palmer, Marinella Ruospo, Patrizia Natale, Valeria Saglimbene, Jonathan C Craig, Fabio Pellegrini, Massimo Petruzzi, Michele De Benedittis, Pauline Ford, David W Johnson, Eduardo Celia, Ruben Gelfman, Miguel R Leal, Marietta Torok, Paul Stroumza, Anna Bednarek-Skublewska, Jan Dulawa, Luc Frantzen, Juan Nin Ferrari, Domingo del Castillo, Jorgen Hegbrant, Charlotta Wollheim, Letitzia Gargano

People with end-stage kidney disease treated with dialysis experience high rates of premature death that are at least 30-fold that of the general population, and have markedly impaired quality of life. Despite this, interventions that lower risk factors for mortality (including antiplatelet agents, epoetins, lipid lowering, vitamin D compounds, or dialysis dose) have not been shown to improve clinical outcomes for this population. Although mortality outcomes may be improving overall, additional modifiable determinants of health in people treated with dialysis need to be identified and evaluated. Oral disease is highly prevalent in the general population and represents a potential and preventable cause of poor health in dialysis patients. Oral disease may be increased in patients treated with dialysis due to their lower uptake of public dental services, as well as increased malnutrition and inflammation, although available exploratory data are limited by small sample sizes and few studies evaluating links between oral health and clinical outcomes for this group, including mortality and cardiovascular disease. Recent data suggest periodontitis may be associated with mortality in dialysis patients and well-designed, larger studies are now required.